1. Home
  2. AQB vs AZTR Comparison

AQB vs AZTR Comparison

Compare AQB & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AQB
  • AZTR
  • Stock Information
  • Founded
  • AQB 1991
  • AZTR 2014
  • Country
  • AQB United States
  • AZTR United States
  • Employees
  • AQB N/A
  • AZTR N/A
  • Industry
  • AQB
  • AZTR Biotechnology: Pharmaceutical Preparations
  • Sector
  • AQB
  • AZTR Health Care
  • Exchange
  • AQB Nasdaq
  • AZTR Nasdaq
  • Market Cap
  • AQB 4.0M
  • AZTR 4.2M
  • IPO Year
  • AQB N/A
  • AZTR 2023
  • Fundamental
  • Price
  • AQB $1.07
  • AZTR $0.36
  • Analyst Decision
  • AQB
  • AZTR Strong Buy
  • Analyst Count
  • AQB 0
  • AZTR 1
  • Target Price
  • AQB N/A
  • AZTR $4.00
  • AVG Volume (30 Days)
  • AQB 55.8K
  • AZTR 7.7M
  • Earning Date
  • AQB 10-28-2025
  • AZTR 11-12-2025
  • Dividend Yield
  • AQB N/A
  • AZTR N/A
  • EPS Growth
  • AQB N/A
  • AZTR N/A
  • EPS
  • AQB N/A
  • AZTR N/A
  • Revenue
  • AQB N/A
  • AZTR N/A
  • Revenue This Year
  • AQB N/A
  • AZTR N/A
  • Revenue Next Year
  • AQB N/A
  • AZTR N/A
  • P/E Ratio
  • AQB N/A
  • AZTR N/A
  • Revenue Growth
  • AQB N/A
  • AZTR N/A
  • 52 Week Low
  • AQB $0.47
  • AZTR $0.32
  • 52 Week High
  • AQB $2.95
  • AZTR $4.33
  • Technical
  • Relative Strength Index (RSI)
  • AQB 36.52
  • AZTR 31.82
  • Support Level
  • AQB $0.98
  • AZTR $0.32
  • Resistance Level
  • AQB $1.13
  • AZTR $0.43
  • Average True Range (ATR)
  • AQB 0.09
  • AZTR 0.07
  • MACD
  • AQB -0.02
  • AZTR -0.01
  • Stochastic Oscillator
  • AQB 16.60
  • AZTR 8.66

About AQB AquaBounty Technologies Inc.

AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: